RxDoctor Payments Data

Caroline Sewell

Acute Care · Nashville, TNNPI 1205235322

Payments from drug & device makers

$943in general payments, 2019–2025

Across 28 payments — averaging $33.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$143
  • Johnson & Johnson$139
  • Cvrx, Inc.$135
  • Boehringer Ingelheim$125
  • E.r. Squibb & Sons, L.L.C.$115
  • Novo Nordisk$100
  • plus $186 from 5 others

What the payments were for

  • Food & beverage$943100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$943 in reported general payments places this provider in the 70th percentile of 738 acute care providers in Tennessee.

See all acute care providers in Tennessee

Medicare billing

Part B allowed, 2024
$47,811
Medicare patients
343
Services billed
803

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban114$123,745
Repatha SureclickEvolocumab75$49,217
XareltoRivaroxaban30$47,981
JardianceEmpagliflozin29$27,700
EntrestoSacubitril/Valsartan14$20,837
Repatha SyringeEvolocumab12$3,314
Metoprolol Succinate97$1,511
Atorvastatin Calcium137$1,216
Isosorbide Mononitrate ErIsosorbide Mononitrate70$1,215
ClopidogrelClopidogrel Bisulfate105$1,096
Losartan Potassium116$900
Carvedilol125$852
Metoprolol Tartrate110$779
Potassium Chloride57$768
Amlodipine Besylate126$727

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$143$123,745114 claims
Johnson & JohnsonXarelto$139$47,98130 claims
Boehringer IngelheimJardiance$125$27,70029 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 738 acute care providers in Tennessee.

Other acute care in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →